Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus.
Zhou S, Williford SE, McGivern DR, Burch CL, Hu F, Benzine T, Ingravallo P, Asante-Appiah E, Howe AYM, Swanstrom R, Lemon SM. Zhou S, et al. Among authors: howe aym. Antiviral Res. 2018 Oct;158:45-51. doi: 10.1016/j.antiviral.2018.07.024. Epub 2018 Aug 3. Antiviral Res. 2018. PMID: 30081054 Free PMC article. Clinical Trial.
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E. Lahser FC, et al. Among authors: howe ay. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64. doi: 10.1128/AAC.00051-16. Print 2016 May. Antimicrob Agents Chemother. 2016. PMID: 26926625 Free PMC article.
Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse.
Bonsall D, Black S, Howe AY, Chase R, Ingravallo P, Pak I, Brown A, Smith DA, Bowden R, Barnes E. Bonsall D, et al. Among authors: howe ay. Infect Drug Resist. 2018 Aug 8;11:1119-1135. doi: 10.2147/IDR.S156581. eCollection 2018. Infect Drug Resist. 2018. PMID: 30127629 Free PMC article.
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. Manns MP, et al. Among authors: howe ay. Gastroenterology. 2014 Aug;147(2):366-76.e6. doi: 10.1053/j.gastro.2014.04.006. Epub 2014 Apr 12. Gastroenterology. 2014. PMID: 24727022 Clinical Trial.
63 results